Baylor College of Medicine's Lillie and Roy Cullen Tower is set to open in 2026. Rendering courtesy of SLAM Architecture

Baylor College of Medicine has collected $100 million toward its $150 million fundraising goal for the college’s planned Lillie and Roy Cullen Tower.

The $100 million in gifts include:

  • A total of $30 million from The Cullen Foundation, The Cullen Trust for Health Care, and The Cullen Trust for Higher Education.
  • $12 million from the DeBakey Medical Foundation
  • $10 million from the Huffington Foundation
  • More than $45 million from members of Baylor’s Board of Trustees and other community donors, including the M.D. Anderson Foundation, the Albert and Margaret Alkek Foundation, and The Elkins Foundation.

“The Cullen Trust for Health Care is very honored to support this building along with The Cullen Foundation and The Cullen Trust for Higher Education,” Cullen Geiselman Muse, chair of The Cullen Trust for Health Care, says in a news release. “We cannot wait to see what new beginnings will come from inside the Lillie and Roy Cullen Tower.”

The Baylor campus is next to Texas Medical Center’s Helix Park, a 37-acre project. Rendering courtesy of BCM

The Lillie and Roy Cullen Tower is set to open in 2026. The 503,000-square-foot tower is the first phase of Baylor’s planned Health Sciences Park, an 800,000-square-foot project that will feature medical education and research adjacent to patient care at Baylor Medicine and Baylor St. Luke’s Medical Center on the McNair Campus.

The Baylor campus is next to Texas Medical Center’s Helix Park, a 37-acre project that will support healthcare, life sciences, and business ventures. Baylor is the anchor tenant in the first building being constructed at Helix Park.

“To really change the future of health, we need a space that facilitates the future,” says Dr. Paul Klotman, president, CEO, and executive dean of Baylor. “We need to have a great building to recruit great talent. Having a place where our clinical programs are located, where our data scientists are, next to a biotech development center, and having our medical students all integrated into that environment will allow them to be ready in the future for where healthcare is going.”

In the 1940s, Lillie and Roy Cullen and the M.D. Anderson Foundation were instrumental in establishing the Texas Medical Center, which is now the world’s largest medical complex.

“Baylor is the place it is today because of philanthropy,” Klotman says. “The Cullen family, the M.D. Anderson Foundation, and the Albert and Margaret Alkek Foundation have been some of Baylor’s most devoted champions, which has enabled Baylor to mold generations of exceptional health sciences professionals. It is fitting that history is repeating itself with support for this state-of-the-art education building.”

The Cullen Foundation donated $30 million to the project. Rendering courtesy of BCM

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers create AI model to tap into how brain activity relates to illness

brainiac

Houston researchers are part of a team that has created an AI model intended to understand how brain activity relates to behavior and illness.

Scientists from Baylor College of Medicine worked with peers from Yale University, University of Southern California and Idaho State University to make Brain Language Model, or BrainLM. Their research was published as a conference paper at ICLR 2024, a meeting of some of deep learning’s greatest minds.

“For a long time we’ve known that brain activity is related to a person’s behavior and to a lot of illnesses like seizures or Parkinson’s,” Dr. Chadi Abdallah, associate professor in the Menninger Department of Psychiatry and Behavioral Sciences at Baylor and co-corresponding author of the paper, says in a press release. “Functional brain imaging or functional MRIs allow us to look at brain activity throughout the brain, but we previously couldn’t fully capture the dynamic of these activities in time and space using traditional data analytical tools.

"More recently, people started using machine learning to capture the brain complexity and how it relates it to specific illnesses, but that turned out to require enrolling and fully examining thousands of patients with a particular behavior or illness, a very expensive process,” Abdallah continues.

Using 80,000 brain scans, the team was able to train their model to figure out how brain activities related to one another. Over time, this created the BrainLM brain activity foundational model. BrainLM is now well-trained enough to use to fine-tune a specific task and to ask questions in other studies.

Abdallah said that using BrainLM will cut costs significantly for scientists developing treatments for brain disorders. In clinical trials, it can cost “hundreds of millions of dollars,” he said, to enroll numerous patients and treat them over a significant time period. By using BrainLM, researchers can enroll half the subjects because the AI can select the individuals most likely to benefit.

The team found that BrainLM performed successfully in many different samples. That included predicting depression, anxiety and PTSD severity better than other machine learning tools that do not use generative AI.

“We found that BrainLM is performing very well. It is predicting brain activity in a new sample that was hidden from it during the training as well as doing well with data from new scanners and new population,” Abdallah says. “These impressive results were achieved with scans from 40,000 subjects. We are now working on considerably increasing the training dataset. The stronger the model we can build, the more we can do to assist with patient care, such as developing new treatment for mental illnesses or guiding neurosurgery for seizures or DBS.”

For those suffering from neurological and mental health disorders, BrainLM could be a key to unlocking treatments that will make a life-changing difference.

Houston-based cleantech unicorn named among annual top disruptors

on the rise

Houston-based biotech startup Solugen is making waves among innovative companies.

Solugen appears at No. 36 on CNBC’s annual Disruptor 50 list, which highlights private companies that are “upending the classic definition of disruption.” Privately owned startups founded after January 1, 2009, were eligible for the Disruptor 50 list.

Founded in 2016, Solugen replaces petroleum-based products with plant-derived substitutes through its Bioforge manufacturing platform. For example, it uses engineered enzymes and metal catalysts to convert feedstocks like sugar into chemicals that have traditionally been made from fossil fuels, such as petroleum and natural gas.

Solugen has raised $643 million in funding and now boasts a valuation of $2.2 billion.

“Sparked by a chance medical school poker game conversation in 2016, Solugen evolved from prototype to physical asset in five years, and production hit commercial scale shortly thereafter,” says CNBC.

Solugen co-founders Gaurab Chakrabarti and Sean Hunt received the Entrepreneur of The Year 2023 National Award, presented by professional services giant EY.

“Solugen is a textbook startup launched by two partners with $10,000 in seed money that is revolutionizing the chemical refining industry. The innovation-driven company is tackling impactful, life-changing issues important to the planet,” Entrepreneur of The Year judges wrote.

In April 2024, Solugen broke ground on a Bioforge biomanufacturing plant in Marshall, Minnesota. The 500,000-square-foot, 34-acre facility arose through a Solugen partnership with ADM. Chicago-based ADM produces agricultural products, commodities, and ingredients. The plant is expected to open in the fall of 2025.

“Solugen’s … technology is a transformative force in sustainable chemical manufacturing,” says Hunt. “The new facility will significantly increase our existing capabilities, enabling us to expand the market share of low-carbon chemistries.”

Houston cleantech company tests ​all-electric CO2-to-fuel production technology

RESULTS ARE IN

Houston-based clean energy company Syzygy Plasmonics has successfully tested all-electric CO2-to-fuel production technology at RTI International’s facility at North Carolina’s Research Triangle Park.

Syzygy says the technology can significantly decarbonize transportation by converting two potent greenhouse gases, carbon dioxide and methane, into low-carbon jet fuel, diesel, and gasoline.

Equinor Ventures and Sumitomo Corp. of Americas sponsored the pilot project.

“This project showcases our ability to fight climate change by converting harmful greenhouse gases into fuel,” Trevor Best, CEO of Syzygy, says in a news release.

“At scale,” he adds, “we’re talking about significantly reducing and potentially eliminating the carbon intensity of shipping, trucking, and aviation. This is a major step toward quickly and cost effectively cutting emissions from the heavy-duty transport sector.”

At commercial scale, a typical Syzygy plant will consume nearly 200,000 tons of CO2 per year, the equivalent of taking 45,000 cars off the road.

“The results of this demonstration are encouraging and represent an important milestone in our collaboration with Syzygy,” says Sameer Parvathikar, director of renewable energy and energy storage at RTI.

In addition to the CO2-to-fuel demonstration, Syzygy's Ammonia e-Cracking™ technology has completed over 2,000 hours of performance and optimization testing at its plant in Houston. Syzygy is finalizing a site and partners for a commercial CO2-to-fuel plant.

Syzygy is working to decarbonize the chemical industry, responsible for almost 20 percent of industrial CO2 emissions, by using light instead of combustion to drive chemical reactions.

------

This article originally ran on EnergyCapital.